Cognitive Changes Associated With Breast Cancer Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00550134 |
Recruitment Status
:
Active, not recruiting
First Posted
: October 29, 2007
Last Update Posted
: November 8, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Breast Cancer Cognitive Side Effects of Cancer Treatments Stage I, II and III A Breast Cancer | Behavioral: Questionnaires, MRI, Comet assay and Cell senescence |
Study Type : | Observational |
Estimated Enrollment : | 80 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Cognitive Changes Associated With Breast Cancer Treatment |
Study Start Date : | October 2007 |
Estimated Primary Completion Date : | December 2018 |
Estimated Study Completion Date : | December 2018 |

Group/Cohort | Intervention/treatment |
---|---|
1, Non Cancer group
A noncancer control group (N=35), frequency matched on age (< 50 and ≥ 50) and education (less than college or some college and above) will also be recruited and evaluated with the same neuropsychological test battery on a schedule that matches the inter-test interval of the patients.
|
Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
Other Names:
|
2 Breast Cancer Patients Scheduled for chemotherapy
We will recruit patients with localized breast cancer undergoing adjuvant chemotherapy for the first time and will test the effects of chemotherapy will be given a battery of neuropsychological tests and an MRI evaluation prior to beginning chemotherapy and approximately one month (plus/minus 4 weeks) following completion of treatment.
|
Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
Other Names:
|
3 Breast Cancer Patients Not Scheduled for Chemotherapy
We will recruit patients with localized breast cancer not undergoing adjuvant chemotherapy.
|
Behavioral: Questionnaires, MRI, Comet assay and Cell senescence
Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
Other Names:
|
- To evaluate changes in cognitive performance pre- to post-chemotherapy in breast cancer patients. [ Time Frame: approximately 4 to 6 months from baseline, depending on chemotherapy regimen ]
- To evaluate associations between changes in frontal cortex and hippocampal volumes and activation patterns and changes in neuropsychological test performance. [ Time Frame: 4 to 6 months ]
- To evaluate the relationship between change in level of oxidative DNA damage markers of cell senescence (Telomere attrition) and changes in volume and activation patterns in prefrontal cortex and hippocampus. [ Time Frame: 4 to 6 months ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Potential subjects for the study will be identified MSKCC's clinic.
Healthy control group participants will be recruited through advertisements and flyers which will be available/advertised in the community. Health control participants will also be recruited by asking survivors if they have a friend who might want to volunteer for the study.
Inclusion Criteria:
- Patient is 18 years of age but not older than 70years of age
- Patient is female
- Patient is able to understand English, through verbal and written communication
- In the judgment of the investigator and/or the consenting professional patient is able to provide informed consent
- Patient has a diagnosis of breast cancer (stage 0, I, II or IIIA-C), limited to localized disease,
- Patient is chemotherapy naïve and is receiving chemotherapy or is scheduled to receive no chemotherapy as part of adjuvant treatment
- Patient does not report history of prior breast or other cancer with the exception of non-melanoma skin cancer and/or participants who completed treatment for a previous cancer at least 5 years ago and have not undergone any chemotherapy.
- Patient is able to undergo MRI scanning (verified with pre MRI Safety Screening form),
- Patient can comfortably fit inside the MRI machine, verified by back to chest measurement no more than 10 inches or bust circumference of no more than 48 inches.
Exclusion Criteria:
- Patient has documented evidence of cognitive compromise (Blessed- Orientation Memory Cognition Test score > 11
- Patient has a history of neurological disorder with cognitive symptoms (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis)
- Patient is Pregnant as confirmed by urine pregnancy test. Participants who are post menopausal or have had a hysterectomy do not need a pregnancy test
- Patient is currently on daily medication for migraine or, insulin-dependent diabetes requiring administration by injection,
- Patient has uncontrollable hypertension as per self report or as documented in the medical record
- Patient has a reported fear of enclosed spaces (Claustrophobia)
- Patient has any of the following items that preclude fMRI evaluation
- Cardiac pacemaker, Joint replacements, Aneurysm clips, Transdermal patched, Aortic clips, Prosthesis, Intracranial bypass clips, Harrington rod , Coronary Artery bypass clips, Biostimulator, Renal Transplant Clips, Bone or joint pins, Other vascular clips or filters, Tissue expander ,Implanted neurostimulators, Metal mesh, Artificial heart valve, Stents, Insulin pump, Wire structures, Electrodes, Shrapnel/bullets, Hearing Aids implant, Implanted electrical devices, IUD, Metal in eyes, Shunts, Ocular Implants, Hair extensions, Hair implants, Tattoos above the waist, Any possible metal in body
- Patient has dentures, body jewelry or wig that they are unable to remove
- History of head injury with evidence of brain injury or loss of consciousness for > 60 minutes or cognitive sequelae
- Untreated or current episode of depression (answering positively to either of the two screening questions from the PHQ-9 (Kroenke, et al., 2001)
- Self-reported sleep disorders that could influence cognitive functioning including sleep apnea and and narcolepsy
- History of Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia disorder (DSM-IV) or substance use disorders (self reported and/or stated in medical record)
- History of schizophrenia, bipolar disorder or substance use disorders
- Patient is unwilling to undergo fMRI component if selected
- Patient has undergone previous chemotherapy treatment
Healthy Control Inclusion Criteria:
- Participant is 18 years of age but not older than 70 years of age,
- Participant is female
- Participant is able to understand English, through verbal and written communication
- In the judgment of the investigator and/or the consenting professional participant is able to provide informed consent
- Patient is able to undergo MRI scanning (verified with pre MRI Safety Screening form)
- Patient can comfortably fit inside the MRI machine, verified by back to chest measurement no more than 10 inches or bust circumference of no more than 48 inches.
Healthy Control Exclusion Criteria:
-Participant has Documented evidence of severe cognitive compromise (Blessed- Orientation Memory Cognition Test score > 11
- Participant has a history of neurological disorder with cognitive symptoms (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis).
- Participant is pregnant as indicated by urine pregnancy test,
- As per self report participant is currently on daily medication for migraine, or , insulin dependent diabetes requiring administration by injection,
- As per self report participant has uncontrollable hypertension,
- As per self report, participant has a reported fear of enclosed spaces (Claustrophobia)
- As per self report, participant has any of the following items that preclude fMRI evaluation Cardiac pacemaker, Joint replacements, Aneurysm clips, Transdermal patched, Aortic clips Prosthesis, Intracranial bypass clips, Harrington rod , Coronary Artery bypass clips, Biostimulator, Renal Transplant Clips, Bone or joint pins, Other vascular clips or filters, Tissue expander ,Implanted neurostimulators, Metal mesh, Artificial heart valve, Stents, Insulin pump, Wire structures, Electrodes, Shrapnel/bullets, Hearing Aids implant, Implanted electrical devices, IUD, Metal in eyes, Shunts, Ocular Implants, Hair extensions, Hair implants, Tattoos above the waist, Any possible metal in body
- As per self report, participant has dentures, body jewelry or wig that they are unable to remove
- As per self report, participant has a history of head injury with evidence of brain injury or loss of consciousness for > 60 minutes or cognitive sequelae
- As per self report, participant has untreated or current episode of depression (answering positively to either of the two screening questions from the PHQ-9 (Kroenke, et al., 2001)
- As per self report, participant has sleep disorders that could influence cognitive functioning including sleep apnea and narcolepsy,
- As per self report, participant has history of Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia disorder (DSM-IV) or substance use disorders
- As per self report, participant has undergone previous chemotherapy treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00550134
United States, New York | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 |
Principal Investigator: | Tim Ahles, PhD | Memorial Sloan Kettering Cancer Center |
Additional Information:
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00550134 History of Changes |
Other Study ID Numbers: |
07-130 |
First Posted: | October 29, 2007 Key Record Dates |
Last Update Posted: | November 8, 2017 |
Last Verified: | November 2017 |
Keywords provided by Memorial Sloan Kettering Cancer Center:
Breast Cancer Quality of life |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |